Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Adam Cribbs has been awarded a prestigious MRC Career Development Award to further his research to identify therapeutic targets for multiple myeloma.

Adam Cribbs

Multiple myeloma (MM) is a cancer of plasma cells that has a varied response rate to treatment and a survival rate of 4-5 years. Poor survival has been attributed to drug resistance therefore identification of novel therapeutic targets for MM that overcome drug resistance is critical.

The MRC Career Development Awards, which are offered to support talented researchers to lead their own research, will enable Adam to build on his research interests in systems biology, immunology and epigenetics.

Specifically, he will develop novel, cost-effective multiplexed single-cell technologies that will provide an understanding of the relationship between the immune system and the MM tumour macroenvironment.

Commenting on his award Adam said: “I’m so pleased to have been offered the MRC award. We need to understand the cellular mechanisms that contribute to drug resistance within MM to be able to deliver better treatments. This award reinforces my belief that in time we will be able to expand the number of potential drug targets for MM, improving quality and longevity of life for patients.”

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.